Table 3.
Effects of FSC-S and FSC-SpEt supplementation on hepatic size and liver function in normal and experimental hypercholesterolemic (HCL) mice
| Groups | Drug dose (%, w/w) | Hepatic weight (g) | Hepatic index | Serum ALT activity (U/L) |
|---|---|---|---|---|
| Normal mice | ||||
| ND | – | 1.69 ± 0.06 | 5.98 ± 0.13 | 53.70 ± 4.30 |
| ND/FSC-S | 9 | 1.90 ± 0.13 | 9.32 ± 0.39** | 42.83 ± 3.06 |
| ND/FSC-SpEt | 9 | 1.85 ± 0.04* | 6.55 ± 0.08** | 42.58 ± 3.75 |
| ND/FF | 0.05 | 2.75 ± 0.05** | 10.00 ± 0.11** | 46.59 ± 4.98 |
| HCL mice | ||||
| ND | – | 1.79 ± 0.06 | 6.11 ± 0.07 | 50.88 ± 1.30 |
| HCBD | – | 2.07 ± 0.05** | 7.12 ± 0.09** | 62.00 ± 3.59* |
| HCBD/FSC-S | 3 | 2.56 ± 0.14## | 8.81 ± 0.47## | 73.78 ± 6.45 |
| 9 | 2.87 ± 0.17## | 11.28 ± 0.51## | 82.63 ± 6.11# | |
| HCBD/FSC-SpEt | 3 | 1.99 ± 0.18 | 6.95 ± 0.15 | 71.50 ± 2.99 |
| 9 | 2.01 ± 0.11 | 7.37 ± 0.13 | 63.25 ± 2.55 | |
| HCBD/FF | 0.05 | 3.46 ± 0.08## | 12.19 ± 0.20## | 110.50 ± 13.06## |
Experimental details were described in Table 1. Mice were fed with ND and HCBD without or with FSC-S, FSC-SpEt, or FF supplementation. Ten days after supplemetnation, hepatic weight and index, as well as serum alanine aminotransferase (ALT) activity were measured. Hepatic index was estimated from the ratio of its weight to body weight × 100. Values given are the means ± SEM, with n = 10. * P < 0.05, ** P < 0.01 vs ND; # P < 0.05, ## P < 0.01 vs HCBD. Statistical significant differences were determined using a one-way ANOVA followed by Dunnett’s multiple comparisons test or post-hoc analysis